{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:59:13Z","timestamp":1790913553876,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":176,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004071","name":"Khon Kaen University","doi-asserted-by":"publisher","award":["AS69003"],"award-info":[{"award-number":["AS69003"]}],"id":[{"id":"10.13039\/501100004071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101300","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:55:41Z","timestamp":1782744941000},"page":"101300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association of glucagon-like peptide 1 receptor and the aggressiveness of extrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"48","author":[{"given":"Yongyot","family":"Varathorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathawee","family":"Chanamarnjuntho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnakrit","family":"Trakoonsenathong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charat","family":"Kusoltech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanyarat","family":"Thithuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakasit","family":"Sa-ngiamwibool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1476-1129","authenticated-orcid":false,"given":"Charupong","family":"Saengboonmee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101300_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","article-title":"Cholangiocarcinoma 2026: status quo, unmet needs and priorities","volume":"23","author":"Banales","year":"2026","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ctarc.2026.101300_bib0002","article-title":"Updated cholangiocarcinoma incidence trends and projections in Thailand by region based on data from four population-based cancer registries","volume":"35","author":"Sahat","year":"2025","journal-title":"Lancet Reg. Health Southeast. Asia"},{"key":"10.1016\/j.ctarc.2026.101300_bib0003","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ctarc.2026.101300_bib0004","doi-asserted-by":"crossref","first-page":"537","DOI":"10.31557\/APJCP.2024.25.2.537","article-title":"Spatio-temporal analysis of cholangiocarcinoma in a high prevalence area of northeastern Thailand: a 10-year large scale screening program","volume":"25","author":"Anchalee","year":"2024","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.ctarc.2026.101300_bib0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ctarc.2026.101300_bib0006","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ctarc.2026.101300_bib0007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.ctarc.2026.101300_bib0008","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ctarc.2026.101300_bib0009","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/gutjnl-2023-330483","article-title":"Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies","volume":"73","author":"Hong","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.ctarc.2026.101300_bib0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ctarc.2026.101300_bib0011","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat. Rev. Drug Disc."},{"key":"10.1016\/j.ctarc.2026.101300_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ctarc.2026.101300_bib0013","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1007\/s11357-024-01494-5","article-title":"Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types","volume":"47","author":"Ungvari","year":"2025","journal-title":"Geroscience"},{"key":"10.1016\/j.ctarc.2026.101300_bib0014","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1007\/s11033-014-3302-7","article-title":"Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues","volume":"41","author":"Chen","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ctarc.2026.101300_bib0015","first-page":"1989","article-title":"Oxaliplatin reverses the GLP-1R-mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling","volume":"18","author":"Chen","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ctarc.2026.101300_bib0016","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64774-2","article-title":"Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo","volume":"14","author":"Trakoonsenathong","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2026.101300_bib0017","doi-asserted-by":"crossref","first-page":"24293","DOI":"10.3390\/ijms141224293","article-title":"Effect of the GLP-1 analog exendin-4 and oxaliplatin on intrahepatic cholangiocarcinoma cell line and mouse model","volume":"14","author":"Chen","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2026.101300_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107064","article-title":"Epidemiology of cholangiocarcinoma","volume":"51","author":"Qurashi","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2026.101300_bib0019","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.3748\/wjg.v11.i22.3392","article-title":"Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100)","volume":"11","author":"Sripa","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ctarc.2026.101300_bib0020","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41571-026-01135-0","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown","volume":"23","author":"Mannucci","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101300_bib0021","article-title":"Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study","volume":"363","author":"Abrahami","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.ctarc.2026.101300_bib0022","article-title":"Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: a large population-based matched cohort study","volume":"38","author":"Krishnan","year":"2024","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"10.1016\/j.ctarc.2026.101300_bib0023","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s12029-025-01330-9","article-title":"Do incretin-based therapies influence the risk of cholangiocarcinoma in type 2 diabetes patients? Insights from a systematic review and meta-analysis","volume":"56","author":"Yonatan","year":"2025","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.ctarc.2026.101300_bib0024","doi-asserted-by":"crossref","first-page":"333","DOI":"10.21037\/atm.2018.07.16","article-title":"Current and future roles of mucins in cholangiocarcinoma-recent evidences for a possible interplay with bile acids","volume":"6","author":"Danese","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ctarc.2026.101300_bib0025","first-page":"649","article-title":"Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact","volume":"22","author":"Park","year":"2009","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ctarc.2026.101300_bib0026","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1440-1746.2008.05332.x","article-title":"Enhanced expression of mucin 6 glycoprotein in cholangiocarcinoma tissue from patients in Thailand as a prognostic marker for survival","volume":"23","author":"Thuwajit","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ctarc.2026.101300_bib0027","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.prp.2010.08.004","article-title":"The expression of MUC mucin in cholangiocarcinoma","volume":"206","author":"Mall","year":"2010","journal-title":"Pathol Res Pr."},{"key":"10.1016\/j.ctarc.2026.101300_bib0028","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.3748\/wjg.v11.i32.4939","article-title":"MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma","volume":"11","author":"Boonla","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ctarc.2026.101300_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.surg.2024.09.052","article-title":"GLP-1R agonist promotes proliferation of neuroendocrine neoplasm cells expressing GLP-1 receptors","volume":"179","author":"Shilyansky","year":"2025","journal-title":"Surgery"},{"key":"10.1016\/j.ctarc.2026.101300_bib0030","article-title":"GLP1R boosts survival, migration and invasion of endometrial cancer cells and protects against ferroptotic cell death","volume":"44","author":"Li","year":"2024","journal-title":"J. Obs. Gynaecol."},{"key":"10.1016\/j.ctarc.2026.101300_bib0031","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24604","article-title":"GLP1R inhibits the progression of endometrial carcinoma through activation of cAMP\/PKA pathway","volume":"36","author":"Li","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.ctarc.2026.101300_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1387243","article-title":"Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422600211X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422600211X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:47:46Z","timestamp":1790912866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829422600211X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":32,"alternative-id":["S246829422600211X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101300","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of glucagon-like peptide 1 receptor and the aggressiveness of extrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101300"}}